IAM
Iambic Therapeutics, Inc. Common StockNASDAQ
Healthcare • Biotechnology
$15.80-1.31%
Close Oct 21, 2026
- Market cap
- $748.93M
- 1 month
- —
- 3 months
- —
- 1 year
- —
- Dividend
- No dividends on record
End-of-day close from stored market data, not a live quote.
About Iambic Therapeutics, Inc. Common Stock
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.
Read more
It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
- Website
- iambic.ai
- Headquarters
- San Diego, CA, United States
- Employees
- 171
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 21, 2026.
Portfolio context
Sign in to see your position size
We’ll show you if IAM is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Institutional coverage is still building for this ticker.
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 0
Get the Full Analysis for IAM
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.